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Understanding the transition from fatty liver (steatosis) to inflammatory and fibrotic steatohepatitis, 
is key to define strategies that alter its progression. Here we show that, when challenged with a 
high fat-high cholesterol diet, mice carrying a mutation that abolishes phosphorylation at Ser196 
(S196A) in the liver X receptor alpha (LXRα) exhibit reduced hepatic inflammation and fibrosis 
despite displaying enhanced steatosis. This is associated with a marked protection against 
cholesterol accumulation. Reduced steatohepatitis in S196A mice involves unique reprogramming 
of the liver transcriptome in response to the diet. Remarkably, impaired LXRα phosphorylation 
uncovers novel diet-specific/phosphorylation-sensitive genes, whose regulation does not simply 
mirror ligand-induced LXR activation. Regulation of these unique, dually responsive genes, is 
associated with the promotion of LXR and cofactor occupancy under a cholesterol-rich diet. 
Therefore, Ser196-LXRα phosphorylation acts as a novel nutritional sensor that triggers a unique 
diet-induced transcriptome, thereby modulating metabolic, inflammatory and fibrotic responses 




Non-Alcoholic Fatty Liver Disease (NAFLD) involves conditions ranging from simple steatosis, 
steatosis accompanied by inflammation with or without fibrosis (steatohepatitis or NASH), 
progression to necrosis, cirrhosis and hepatocellular carcinoma promoting liver-related mortality 
(1). NAFLD is characterized by hepatic triglyceride and cholesterol accumulation without significant 
alcohol consumption. Steatosis alone is considered relatively benign, but its transition to NASH 
represents a key step into further liver damage, which without intervention can lead to organ 
transplantation. However, the mechanisms underlying this transition are poorly understood. 
NAFLD is strongly associated with obesity, insulin resistance and type 2 diabetes affecting 20-30% 
of the adult population in the West (1). Therapies such as insulin sensitizers, or lipid-lowering 
drugs are aimed at treating these associated conditions and only display limited efficacy. Indeed, 
effective NAFLD therapies are currently lacking and restricted to weight loss through lifestyle 
modifications (2). Therefore, identifying factors that modulate the transition to NASH is crucial for 
the development of novel treatments directly targeting NAFLD. 
 
LXRα and LXRβ lipid-activated transcription factors heterodimerise with the Retinoid X Receptor 
(RXR) to control cholesterol and fatty acid homeostasis (3). In addition, LXRs act as modulators of 
inflammation and immunity (4) and show anti-inflammatory and anti-fibrotic activities in acute liver 
disease models (5,6). Besides ligand binding, LXR activity is modulated by post-translational 
modifications (7). We and others previously showed that LXRα is phosphorylated at Ser196 
(Ser198 in the human homolog) (8–10) and that ligand-induced LXRα phosphorylation at this site 
alters its activity in a gene-specific manner (8,10). However, the physiological consequences of 
LXRα phosphorylation remain unknown. Here, we identify global LXRα phosphorylation at Ser196 








LXRα-S196A mice exhibit enhanced steatosis  
As we previously identified in macrophages (8,10), LXRα is phosphorylated at Ser196 (mouse) 
within a motif not present in LXRβ (Fig. S1A), in mouse (Fig. 1A) and human liver (Fig. S1B). To 
understand the impact of LXRα phosphorylation in response to a pathogenic diet, we generated a 
global knock-in mouse carrying a homozygous serine-to-alanine mutation at Ser196 (S196A) that 
impairs its phosphorylation (Fig. 1A and S1C-E). This has little effect on hepatic metabolism on a 
chow diet given that mutant mice have no apparent dysmorphic phenotype, display similar 
developmental growth to matching wild-type mice (WT) (not shown), and comparable hepatic lipids 
or other metabolic parameters on this diet (Table S1).  
Cholesterol metabolites are known LXR endogenous ligands (11) and diets with a high cholesterol 
content enhance LXR activity in vivo (12). Given that cholesterol induces LXRα phosphorylation 
(8), we hypothesised that LXRα phospho-mutant animals respond differently to a high fat-high 
cholesterol (HFHC) diet (13). Total body weight, plasma insulin and glucose levels were similar 
between S196A and WT mice fed a HFHC diet (Table S2). Consistent with LXRα role in hepatic 
steatosis (3), S196A mice displayed higher levels of hepatic, but not plasma, Non-Esterified Fatty 
Acids (NEFAs) and triglycerides than WT mice (Fig. 1B, S1F). Indeed, S196A mice showed 
enhanced micro and macrovesicular hepatic steatosis featuring more and larger lipid droplets (Fig. 
1C-E) and enhanced expression of lipid droplet genes (Fig. S1G). Increased steatosis was 
associated with enhanced hepatic expression of the sterol response element binding protein 1 
(Srebp1c) lipogenic transcription factor, and other LXR target genes involved in fatty acid synthesis 
(fatty acid synthase, Fas) (Fig. 1F). In contrast, other genes such as Cd36, involved in fatty acid 
uptake were not affected, recapitulating the gene selective effects of LXRα phosphorylation in 
macrophages we previously identified (8,10). Given that plasma NEFAs, triglycerides and insulin 
levels do not differ between genotypes (Fig. S1F and Table S2), increased hepatic fat 
accumulation in S196A mice likely results from enhanced de novo lipogenesis (Fig. 1G) as 
observed in other LXR models (14). S196A mice also showed an increase in the expression of 
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stearoyl-CoA desaturase-1 (Scd1) (Fig. 1F), which catalyses the production of monounsaturated 
fatty acids. This led us to investigate whether changes in LXRα phosphorylation alter hepatic fatty 
acid composition, particularly since the types of fatty acids that accumulate in the liver during 
steatosis are thought to modulate the development of NAFL and its progression to NASH (15). 
Consistent with the changes in gene expression, S196A livers showed an increase in the total 
amount of saturated as well as unsaturated fatty acids, specifically ω9 and certain ω6 fatty acid 
species (Fig. 1h and Table S3). Altogether, these results demonstrate that LXRα phosphorylation 
deficiency at S196 induces hepatic steatosis and alters fatty acid composition in response to a 
HFHC diet.  
 
Impaired LXRα phosphorylation attenuates diet-induced hepatic inflammation and fibrosis 
Diet-induced hepatic steatosis precedes inflammation and progression to fibrosis in experimental 
models (16). Strikingly, despite the increased steatosis, S196A mice displayed less inflammation 
(Fig. 2A) and significantly less collagen deposition than their WT counterparts (Fig. 2B). This was 
associated with a significant decrease in the expression of several pro-inflammatory and pro-
fibrotic mediators, such as Oncostatin M (Osm), Chemokine (C-X-C motif) ligand 1 (Cxcl1) and 
Osteopontin (Spp1) and genes involved in collagen synthesis (Col1a1 and Tgfb2) (Fig. 2C). Again, 
consistent with the reported gene specific effects on LXRα-modulated gene expression, only a 
subset of the genes analysed was affected by the S196A mutant (Fig. 2C and not shown). Notably, 
reduced levels of inflammatory and fibrotic genes in S196A mice were revealed mostly upon 
exposure to the cholesterol-rich diet while basal expression levels on chow were largely unaffected 
(Fig. 2D). This likely reflects a modulatory role for LXRα phosphorylation in diet-induced 
transcriptional responses.   
 
Pathways implicated in the pathogenesis of lipid-induced liver damage, including apoptosis, lipid 
peroxidation and macrophage content, were similar between genotypes (Fig. S2A-C). In addition to 
these, prolonged adaptive endoplasmic reticulum (ER) stress is a known adaptive mechanism 
allowing cells to survive upon physiological changes requiring altered rates of protein folding. 
Notably, ER stress not only promotes steatosis but also modulates hepatic fibrosis (17). 
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Expression of factors involved in the activation of ER stress, such as the UPR target gene C/EBP 
homologous protein (Chop) and the Activating Transcription Factor (Atf3) or the spliced X-box-
binding protein-1 (Xbp-1), was reduced in S196A mice (Fig. 2E), suggesting these animals could 
be protected from lipotoxicity through a reduction in ER stress. Overall, these findings demonstrate 
that blocking LXRα-phosphorylation at S196 attenuates lipid-induced hepatic inflammation and 
fibrosis despite the observed enhanced steatosis.  
 
LXRα phospho-mutant mice are protected from dietary cholesterol accumulation 
Free cholesterol can act as an hepatotoxic agent (18) that induces collagen deposition in hepatic 
fibrosis (19). In striking contrast to WT mice, S196A mice challenged with a HFHC diet were 
protected from plasma and hepatic cholesterol accumulation (Fig. 3B). This was accompanied by a 
20% reduction in liver weight in S196A livers compared to WT controls (Table S2). Thus, we next 
investigated expression of genes involved in cholesterol metabolism pathways that could be 
altered by the phospho-mutant LXRα, some of which are already well-characterised targets of 
LXRα (3). Reduced hepatic and plasma cholesterol levels were associated with decreased 
expression of cholesterol efflux transporter Abcg1 (Fig. 3C), reflecting a dampened response to the 
cholesterol-rich diet (Fig. 3D). Notably, S196A mice showed a unique response to the HFHC diet 
regarding the upregulation of Abcg5 (Fig. 3C,D), a transporter mediating hepatobiliary cholesterol 
secretion (20) and a well-characterised target of LXRα (3). No difference was observed in the 
levels of genes involved in cholesterol intestinal absorption and excretion (Fig. S2D), an important 
means by which LXR controls cholesterol homeostasis (3), nor in the expression of other nuclear 
receptors regulating lipid metabolism (Fig. S2E and not shown). Thus, the reduced cholesterol 
accumulation in S196A mice is likely due to increased hepatobiliary secretion of cholesterol. 
Moreover, in contrast to the strong repression of the cholesterogenic transcription factor Srebp2 
and its target gene Ldlr by dietary cholesterol seen in WT mice (Fig. 3E), these genes were largely 
unaffected by the diet in S196A mice, mirroring the unchanged hepatic cholesterol levels in these 
animals in response to diet (Fig. 3A). Overall, these differences in gene expression further reflect 
how the response to a cholesterol-rich diet differs between genotypes. 
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Intracellular cholesterol accumulation activates the unfolded protein response pathway in the ER 
(21), inhibiting protein transport to the Golgi to re-establish ER function (22). One gene linking 
cholesterol metabolism and ER stress is Tm7sf2, which not only participates in cholesterol 
biosynthesis as a 3β-hydroxysterol Δ14-reductase but also acts as an ER sensor by triggering anti-
inflammatory pathways (23). Consistent with a decreased hepatic inflammation (Fig. 2A), Tm7sf2 
expression was enhanced in S196A mice exposed to the diet while other genes involved in 
cholesterol biosynthesis were largely unaffected Fig. S2F). This suggests cholesterol modulation of 
ER stress responses, rather than cholesterol biosynthesis itself, is altered in S196A mice. 
 
Because oxysterols (oxidised cholesterol derivatives some of which act as LXR ligands (11)) have 
been reported to be enhanced in NAFLD patients (24), we next examined the levels of these 
metabolites in both WT and S196A genotypes. LXRα phospho-mutant mice showed significantly 
reduced levels of most of the plasma oxysterols examined (Fig. 3F), consistent with the reduced 
signs of hepatic inflammation and fibrosis (Fig. 3C). These differences in oxysterol levels 
associated with induced Cyp7b1 expression (Fig. 3C), an enzyme involved in oxysterol catabolism 
(25), while enzymes implicated in oxysterol synthesis remained unaffected (not shown). Overall, 
these findings suggest inhibition of LXRα phosphorylation acts as a novel molecular sensor of 
dietary cholesterol in the progression to steatohepatitis.  
 
LXRα-S196A reprograms hepatic gene expression and uncovers a novel diet-induced LXRα 
transcriptome 
To better understand the disparity in diet-induced responses between genotypes and identify novel 
pathways sensitive to LXRα phosphorylation, we assessed transcriptomic differences by RNAseq 
analysis. Principal component analysis evidenced that transcriptomes of WT and S196A mice are 
substantially different, especially under a cholesterol-rich diet (Fig. 4A). Transcriptomic analysis 
revealed 668 genes whose hepatic expression is significantly altered in the mutant mice fed a 
HFHC diet (Fig. 4B,C and Fig. S3). Remarkably, there is minimal overlap between the genes 
modulated by LXRα phosphorylation at S196A in chow and HFHC diets, further reflecting on a 
genome-wide scale the distinct response exerted by S196A mice to the metabolic challenges 
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posed by a cholesterol-rich diet. Pathway enrichment analysis confirmed our initial findings and 
showed induction of genes in lipid metabolism (Fig. 4D,E). Additional interrogation of our datasets 
revealed that in addition to increased expression of enzymes involved in fatty acid synthesis 
(Srebf1, Fas, Fig. 1F), S196A expression increased the hepatic levels of enzymes involved in fatty 
acid elongation (Elovl3, Elovl5) and fatty acid oxidation, with a trend towards increased levels of 
fatty acid desaturation enzyme Fads1 (Fig. 4F). These changes likely contribute to the distinct 
hepatic fatty acid profile present in S196A mice (Fig. 1H). Interestingly, expression of most of these 
enzymes is severely repressed by the HFHC diet (Fig. S4a) further highlighting the modulatory role 
exerted by LXRα-S196. Also corroborating previous analyses, the phospho-mutant mice showed a 
robust decrease in the levels of wound healing and fibrotic mediators including several collagen 
genes and enzymes responsible for collagen stabilisation (Fig. 4D,G). Importantly, gene 
expression changes in response to a HFHC diet appeared to be substantially different between 
WT and S196A mice (Fig. S4B), further supporting that impaired phosphorylation of LXRα-S196 
alters the susceptibility to diet-induced hepatic injury by inducing a distinct hepatic transcriptome. 
Moreover, expression of a subset of genes involved in extracellular matrix remodelling and tissue 
regeneration that distinguish between low-risk/mild and high-risk/severe NAFLD amongst pre-
symptomatic patients (26) was remarkably different between genotypes (Fig. 4H). This suggests 
changes in LXRα phosphorylation could alter pre-clinical NAFLD progression. Importantly, most of 
these genes are involved in extracellular matrix remodelling and tissue regeneration, emphasizing 
a role for Ser196-LXRα phosphorylation in the regulation of these pathways. 
 
Genes showing the strongest difference in expression between WT and S196A genotypes were 
confirmed in a separate set of mice (Fig. 4I,J). Notably, the majority of these genes are modulated 
by LXRα phosphorylation only in a cholesterol-rich environment (Fig. S4C,D) and have not been 
previously reported to be regulated by LXR. One such gene, Ces1f, is a member of the 
carboxylesterase 1 family that hydrolyses cholesterol esters and triglycerides and controls hepatic 
lipid mobilization (27,28). Despite previous studies showing Ces1f is not regulated by LXR ligands 
(29), we now clearly demonstrate Ces1f is highly sensitive to LXRα phosphorylation, preferentially 
in the context of a HFHC diet (Fig. 4I and S4C). Other Ces1 members are also differentially 
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regulated by the LXRα phospho-mutant specifically in a cholesterol-rich setting (Fig S4E). 
Altogether, these data highlight the relevance of LXRα phosphorylation in modulating 
transcriptional responses to dietary cholesterol. 
 
Identification of novel LXR binding sites in dual LXRα phosphorylation/diet-sensitive genes 
To better understand the differential gene regulation resulting from LXRaS196A expression, we 
next examined whether changes at LXRa phosphorylation at S196 affect LXR occupancy at 
selected genes in the context of a cholesterol-rich diet. In silico analysis of the Ces1f gene 
identified a DR4 sequence (AGGTCTatttAGTTCA), resembling the consensus LXRE (30), that was 
preferentially bound by LXR, but not RXR, in HFHC-fed S196A livers (Fig. 5A). This was 
associated with increased RNA Polymerase II (Pol II) and phosho-Ser2 Pol II (pSer-Pol II) 
occupancy indicating an enhanced transcriptional initiation and elongation respectively occurring at 
the Ces1f locus (Fig. 5D). A similar binding pattern was observed for a different DR4 sequence 
identified in Cyp2c69 (GGGTCAagtgAGGTTA), another gene whose expression is enhanced in 
S196A mice (Fig. 4C,I) but not regulated by LXR ligands (31). In contrast, occupancy by both LXR 
and RXR to the well-established LXRE in Srebp-1c gene was induced (Fig. 5C), as was Pol II and 
pSer-Pol II (Fig. 5D). This shows impaired LXRαS196 phosphorylation allows the transcriptional 
activation of genes containing degenerated DR4 sequences without affecting RXR occupancy. The 
novel sequences identified here were revealed by the relative homology to reported LXREs in 
response to LXR ligands in the context of a chow diet (30), given these are the only ChIPseq LXR 
analyses available but bearing in mind that ligand-induced responses may not phenocopy binding 
patterns in response to a cholesterol-rich diet. Indeed, ChIPseq analysis in WT mouse livers 
treated with an LXR ligand on a chow diet shows very little to no presence of LXR at the Ces1f and 
Cyp2c69 DR4 sequences identified (not shown), further supporting that both phosphorylation 
status of LXRα and diet environment are critical for the regulation of these genes.  
 
Molecular modelling studies suggest that phosphorylation of LXRα at S198 (murine S196) induces 
a structural change in the hinge region of the receptor (8,10). Previously, we showed that upon 
LXR ligand activation, phosphorylation affects the transcriptional activity of LXRα by modulating 
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the binding of the NCoR corepressor to phospho-sensitive genes (8). We were unable to detect 
differences in NCoR occupancy in mice exposed to the HFHC diet (not shown), suggesting 
responses to cholesterol in vivo involve other transcriptional players whose interaction with LXRα 
is sensitive to its phosphorylation status. Indeed, TBLR1, which participates in nuclear receptor 
cofactor exchange (32) and modulates LXR target gene expression in hepatic cells (33), was found 
to preferentially bind to LXRα-S196A (Fig. S5A,B). Consistently, TBLR1 occupancy was 
significantly enhanced in S196A livers exposed to the HFHC diet (Fig. 5A,B,C) suggesting this is 
an important component facilitating the transcription of these genes by the LXRα phospho-mutant 
in the context of a cholesterol rich diet. These data collectively indicate that disrupting LXRα 
phosphorylation at Ser196 affects diet-induced responses in liver and reveals LXR target genes 
likely through differential binding of LXR and TBLR1 to novel target sequences.  
 
DISCUSSION 
The transition between relatively benign fatty liver steatosis to inflammatory and fibrotic 
steatohepatitis remains poorly understood. The role of LXRα in promoting fatty acid and 
triglyceride accumulation is well established (3) and has proven a major obstacle in the 
development of LXR ligands as therapeutics against metabolic and cardiovascular disorders (3). 
On the other hand, the hepatic anti-fibrotic and anti-inflammatory actions of LXRs in animal models 
of advanced fibrosis had shed light into additional pathways these receptors modulate in the 
progression to steatohepatitis (5,34). Based on the idea of reversing hepatic lipid accumulation, 
pharmacological antagonism of LXRs has been proposed as an effective therapy against NAFLD. 
For instance, a liver selective LXR inverse agonist SR9238 suppresses hepatic fatty acid synthesis 
and lipid accumulation leading to alleviated hepatic inflammation and fibrosis in an obese rodent 
model (35,36). However, it remained to be defined how LXR affects the transition to early fibrotic 
inflammatory stages of NAFLD in the context of a fatty liver, which is more clinically relevant. 
Previous studies focused their efforts at establishing changes in LXRα expression and reported 
induced levels of LXRα present in steatotic, inflammatory and fibrotic livers (37,38). These could, 
however, represent an adaptive or a maladaptive/pathogenic response to the ongoing cellular and 
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molecular changes. Others studies however, have shown that LXRα is the only nuclear receptor 
whose expression is unaffected during progression to steatohepatitis (39). These contradictions 
highlight the need for further studies investigating how LXRs affect this chronic liver disease. We 
now propose that changes in LXRα phosphorylation play a crucial role in these transitional stages 
of the disease.  
Regardless of changes in gene expression, changes in posttranslational modifications of 
the receptor could impact on the progression of the disease. Posttranslational modifications are a 
powerful means by which the activity and function of nuclear receptors can be altered. Despite the 
key importance of certain nuclear receptors in maintaining metabolic homeostasis, our 
understanding of how these modifications impact on metabolic diseases is scarce (7). Notably, the 
physiological consequences of LXRα phosphorylation, sumoylation and acetylation have only been 
studied in vitro or non-specifically in animal models by pharmacologically or genetically altering the 
enzymes enhancing or inhibiting these modifications (7). To directly address the impact of LXRα 
phosphorylation on NAFLD progression, we generated a novel mouse model harbouring an S196A 
mutation that disrupts LXRα phosphorylation at Ser196.  
Here, we report for the first time that disrupting Ser196-LXRα phosphorylation affects 
hepatic diet induced responses by attenuating progression to steatohepatitis despite existing lipid 
accumulation. Importantly, LXRα phosphorylation at this residue dictates transcriptional responses 
to a HFHC diet that promotes early stages of NAFLD. Despite abundant triglyceride and NEFA 
accumulation, consistent with an increased de novo lipogenesis gene program (Fig. 1 & S1), 
S196A mice exhibit significantly less hepatic inflammation and fibrosis than WT animals (Fig. 2). 
This protective phenotype is associated with a dramatic reduction in hepatic and plasma 
cholesterol (Fig. 3) and a robust repression of numerous pro-inflammatory and pro-fibrotic 
mediators, including eleven collagen species, Lysyl oxidase (LOX) and lysyl oxidase-like proteins 
(LOXLs) responsible for collagen stabilisation through irreversible crosslinking (40,41) (Figs. 2 & 
4). This is the first time Lysyl oxidase (LOX) and lysyl oxidase-like proteins (LOXLs) enzymes, 
which promote fibrosis progression and limit its reversibility (40), have been linked to LXRα.  
Impaired LXRα phosphorylation uncovers novel diet-specific/phosphorylation-sensitive 
genes, i.e. genes responsive to changes in LXRα phosphorylation, mostly in the context of a 
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cholesterol-rich diet (Fig. 4 & S4). Additionally, these genes have not been reported to be 
traditional ligand-modulated LXR targets suggesting the regulation of these identified genes does 
not simply phenocopy ligand-induced LXR activation. For instance, previous studies failed to show 
Ces1f regulation by LXR ligands (29) whereas we now demonstrate Ces1f is highly sensitive to 
LXRα phosphorylation in the context of early stages of steatohepatitis promoted by a HFHC diet 
(Fig. 4I & S4C). Ces1 has been recently shown to be protective from liver inflammation and injury 
(42) and its hepatic deficiency strongly increases susceptibility to cholesterol-driven liver injury 
(43). However, the specific contribution by the carboxylesterase 1 family member Ces1f in NAFLD 
progression has not been addressed. In addition to Ces1f, other Ces1 members (Ces1b, Ces1c, 
Ces1d, Ces1e) are differentially regulated by the LXRα phospho-mutant, most of which are only 
revealed to be sensitive to LXRα phosphorylation in a cholesterol-rich environment (Fig. S4E). 
Interestingly, the form previously shown to be induced by LXR ligands in liver, Ces2c (29), does 
not vary in S196A mice regardless of the diet (Fig S4E), emphasizing that LXRα phosphorylation-
sensitive genes in response to diet are not necessarily responsive to LXR ligands and vice versa. 
Impaired LXRα phosphorylation reveals unique LXRα phosphorylation/diet sensitive target 
genes associated with differential binding of LXR and TBLR1 to novel target sequences. 
Interestingly, our transcriptomic analysis showed that TBLR1 is neither regulated by changes in 
LXRα phosphorylation nor by exposure to the cholesterol-rich diet. TBLR1 activity itself is subject 
to regulation by posttranslational modifications. Perissi and colleagues demonstrated that TBLR1-
S193 is a target of Protein Kinase Cδ-mediated phosphorylation, which happens in situ on the 
promoters of its regulated genes, and leads to the release and degradation of NCoR/SMRT (44). 
This further supports the idea that posttranslational modifications are used as a quick, reversible, 
targeted way to regulate the transcriptional machinery. 
It is important to note that hepatic LXR binding at gene regulatory sites has never been 
explored in a cholesterol-rich diet setting before (30,45). Several recent studies have established 
that altered metabolic states promote epigenomic changes, through chromatin modifications both 
in animal models fed fat-rich diets and in obese and diabetic individuals(46–48). These 
modifications affect chromatin accessibility and are considered to act as a “metabolic imprint” that 
is able to alter metabolic disease risk, such as diabetes and NAFLD. Our findings suggest that the 
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LXRα phosphorylation mutant takes advantage of these changes in the chromatin landscape to 
alter dietary transcriptional responses.   
 
Overall, LXRα phosphorylation at Ser196 acts as a novel nutritional sensor that promotes a unique 
diet-induced transcriptome that modulates metabolic, inflammatory and fibrotic responses key in 
NAFLD progression. Understanding how this and other posttranslational modifications of LXRs are 




Generation of the S196A transgenic animal models  
The S196A floxed (S196Afl/fl) mouse line was generated by Ozgene Pty Ltd (Bentley WA, 
Australia). The genomic sequence for the murine LXRα (Nr1h3) gene was obtained from the 
Ensembl Mouse Genome Server (http://www.ensembl.org/Mus_musculus/), Ensembl gene ID: 
ENSMUSG00000002108. The mutant fragment, located on Exon 5, contains a serine-to-alanine 
mutation at Ser196 introduced by site-directed mutagenesis. The point-mutant exon was delivered 
into an intronic site inside the targeting vector, placed in opposite orientation and thus without 
coding capacity (Fig. S1A). The targeting construct was electroporated into the Bruce4 C57BL/6 
ES cell line. Homologous recombinant ES cell clones were identified by Southern hybridization and 
injected into BALB/cJ blastocysts. Male chimeric mice were obtained and crossed to C57BL/6J 
females to establish heterozygous germline offsprings on a pure C57BL/6 background. The 
germline mice were crossed to a FLP Recombinase mouse line (49) to remove the FRT flanked 
selectable marker cassette (Flp’d mice). Flp’d mice were then crossed with a transgenic C57BL/6 
mouse strain carrying a Cre recombinase under the PGK-1 promoter (50), resulting in the inversion 
and insertion of the lox-flanked mutated (loxP) vector exon 5 region in the sense orientation, and 
deletion of the wild-type (WT) sequence in most adult cell lineages (S196A mice) while WT 
matching controls carry the WT sequence in the sense orientation (Fig. S1D). Mice were 
genotyped by PCR analysis of ear biopsies (Fig S1D,E) using the Jumpstart Taq DNA Polymerase 
(Sigma Aldrich) and the following primers: wild-type (WT) forward 
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5’GGTGTCCCCAAGGGTGTCCT, reverse 5’ AAGCATGACCTGCACACAAG and mutant forward 
5’ GGTGTCCCCAAGGGTGTCCG. Animals were housed together and maintained in a pathogen-
free animal facility in a 12-h light-dark cycle. All procedures were carried under the UK’s Home 
Office Animals (Scientific Procedures) Act 1986. 
 
Diet studies and tissue collection 
Ten-week old WT and S196A female mice were fed ad libitum a High Fat-High Cholesterol (HFHC) 
diet (17,2% Cocoa Butter, 2,8% Soybean Oil, 1,25% Cholesterol, 0,5% Sodium Cholate; AIN-
76A/Clinton Diet #4, Test Diet Limited, UK) or a chow diet (18% Protein, 6.2% Fat, 0% Cholesterol; 
Harlan Laboratories) for 6 weeks. Mice were fasted overnight prior to sacrifice. Blood was collected 
by cardiac puncture and plasma was aliquoted and frozen at -80 °C. Tissue was dissected, 
weighted and frozen at -80 °C or placed in RNAlater (Sigma Aldrich).  
 
Plasma and hepatic lipid determination 
Frozen livers (50 mg) were homogenized in 250 mM sucrose, 2 mM EDTA, 10 mM Tris buffer 
using ceramic beads in a Minilys Tissue Homogenizer (Bertin Corp.). Triglycerides and Cholesterol 
were extracted with Isopropanol or Chloroform:Methanol (1:1) solutions, respectively. Non 
Esterified Free Fatty Acids (NEFAs) were extracted by incubating liver homogenates with 1% 
Triton-100X and chloroform solution. Plasma and hepatic total cholesterol, triglyceride levels 
(Wako Diagnostics), and NEFAs (Abcam) were determined by colorimetric enzymatic assay kits as 
per the manufacturer’s recommendations. Hepatic lipid content was normalized to protein 
concentration.  
 
Oxysterol LC-MS analysis  
Protein was precipitated from plasma with 480 pM of the appropriate internal standards (Avanti 
Polar Lipids, Alabaster, AL, USA). Sample clean-up was conducted off-line, using solid phase 
extraction (SPE, SilactSPE C18 100 mg, Teknolab, Ski, Norway) and dryed at 30 °C, re-dissolved 
in 2-propanol and treated as described (51). Samples and calibration solutions were analysed 
using an Ultimate 3000 UHPLC connected to an Advantage QqQ (both Thermo Fisher, Waltham, 
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MA, USA) equipped with an Automatic filtration and filter back-flush SPE add-on, as described 
(52). 
 
Determination of hepatic fatty acid profiles 
Liver fatty acid content from WT and S196A mice fed a HFHC diet were assayed by gas liquid 
chromatography with flame ionization detection by AS Vitas (Oslo, Norway).	 Internal standard 
triheptadecanoin was added and fatty acids were methylated into methyl esters (FAMEs) with 
MeOH HCl and extracted with hexane. Analyses were performed on an Agilent 7890A GC and a 
7683B automatic liquid sampler and flame ionization detection (Agilent Technologies, USA). 
Separations were obtained using a SP-2380 column. Fatty acid content was calculated based on 
the area percentage of peaks and response factors relative to 18:0. An external standard 
containing known amounts of relevant FAMEs (Supelco 37 component FAME Mix) was included in 
each run to correct for differences in fatty acid response factors. Results were normalized to 
protein content. The ratio of 16:0 to 18:2 n-6 was used to calculate a de novo lipogenesis index 
(53) . The total saturated fatty acid content was calculated as the sum of 12:0, 14:0, 15:0, 16:0, 
17:0, 18:0, 20:0 and 22:0. The total unsaturated fatty acid content was calculated as the sum of ω9 
(16:1 c9, 18:1 c9, 20:1 n-9), ω6 (18:2 n-6, 18:3 n-6, 20:2 n-6, 20:3 n-6, 20:4 n-6) and ω3 (18:3 n-3, 
20:5 n-3, 22:5 n-3, 22:6 n-3) fatty acids. 
 
 
RNA extraction and quantification.  
Total RNA from was extracted with TRIzol Reagent (Invitrogen). Sample concentration and purity 
was determined using a NanoDrop™ 1000 Spectrophotometer and cDNA was synthesized using 
the qScript cDNA Synthesis Kit (Quanta). Specific genes were amplified and quantified by 
quantitative PCR (qPCR), using the PerfeCTa SYBR Green FastMix (Quanta) on an MX3000p 
system (Agilent). Primer sequences are available upon request The relative amount of mRNAs 
was calculated using the comparative Ct method and normalized to the expression of cyclophilin 
(54). Mouse Cytokines & Chemokines	 RT2 Profiler PCR Arrays were performed per the 
manufacturer's instructions (Qiagen). Briefly, cDNA was synthesized using an RT2 HT first strand 
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kit (Qiagen), and qPCR analysis was performed using RT2 SYBR Green ROX™ qPCR Mastermix 
(Qiagen). The relative amount of mRNAs was calculated using the comparative Ct method and 
normalized to an average of five housekeeping genes. The full list of genes analysed with these 
arrays can be found at Qiagen’s website. 
 
Protein isolation, immunoprecipitation, and immunoblotting 
Single cell suspensions from livers were immunoprecipitated with antibodies that specifically 
recognise human (LXRα, ab41902 Abcam) or murine (LXRα/β) (55) receptors previously 
crosslinked to a column with Protein A/G Agarose following the manufacturer’s protocol (Pierce). 
Phospho-Ser196 specific rabbit polyclonal antibody (8), mouse α-LXRα monoclonal antibody 
(ab41902, Abcam), α-Hsp90 polyclonal (sc-7947, Santa Cruz) were used for immunoblotting. Anti-
rabbit (PO448, Dako) or anti-mouse (NA931VS, GE Healthcare) horseradish-peroxidase-tagged 
antibodies were used for secondary binding and chemiluminescence (ECL 2 Western Blotting 
Substrate, Pierce) was used to visualise proteins.  
For co-immunoprecipitation studies, HEK293T-LXRα, HEK-S198A or HEK 293T-Vo cells 
expressing FLAG-tagged receptors as in (8) were lysed and crude nuclear pellets were obtained. 
Supernatants containing nuclear proteins were incubated with FLAG antibody-conjugated agarose 
beads (Invitrogen). Bead-associated proteins associated were eluted in TBS and immunoblotted 
with α-TBLR1 (ab190796, Abcam) or α-LXRα (ab41902, Abcam) antibodies.    
 
Histopathological analysis 
Formalin-fixed, paraffin-embedded mouse livers were cut and stained with hematoxylin and eosin 
(H&E) or Picrosirius Red (Abcam) dyes. Liver histology was blindly scored by an independent 
histopathologist based on three semiquantitative items: steatosis (0–3), lobular inflammation (0–3) 
and hepatocellular ballooning (0–2) (not shown) (56). Stained sections were scanned with 
NanoZoomer Digital slide scanner (Hamamatsu) and quantification of Picrosirius red-stained areas 
was performed using Image J on three independent areas per section. Data is represented as the 
average positively-stained percent of area of interest. Apoptosis was detected in liver tissue 
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sections using a terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assay 
(R&D Systems). Sections were imaged using the Axio Imager.A1 Digital Microscope (Zeiss). 
 
Lipid droplet identification 
Identification and quantification of lipid droplets were made with the help of Eli (Easy Lipids) v1.0, 
an in-house software developed between the Multiscale Cardiovascular Engineering (MUSE) and 
Dr Pineda-Torra’s groups at UCL. This software uses a method based on the Hough Transform 
(57) for the identification of the droplets estimating the centres and radii of each of them. A final 
report is generated with the dimensions of the droplets (i.e. diameter and area) including a 
histogram describing the frequency of lipid vacuoles within specified diameter ranges. A trial of Eli 
v1.0 is currently available upon request on the MUSE website at UCL 
(www.ucl.ac.uk/muse/software). 
 
Lipid peroxidation quantification 
Thiobarbituric Acid Reactive Substances (TBARS) were measured in about 25 mg of frozen liver 
as per manufacturer’s instructions (Cayman Chemicals). Briefly, lipid peroxidation was quantified 
by the reaction of Malondialdehyde (MDA), a product of lipid peroxidation, with thiobarbituric acid 
(TBA) to form a colorimetric (532 nm) product, proportional to the MDA present. Levels of MDA 
were normalised to total protein levels, quantified by the Bradford Assay.  
 
LXRα proteomic analysis 
HEK293T cells expressing vector only (Vo), FLAG-hLXRα or FLAG-hLXRα-S198A (58) were 
treated with 1 µM T0901317 for 8 hours. Purification of protein complexes, Multidimensional 




Fresh mouse livers were crosslinked with 2 mM disuccinimidyl glutarate (DSG) for 30 min, followed 
by 1% formaldehyde for 10 min at room temperature. The reaction was stopped with glycine at a 
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final concentration of 0.125 M for 5 min. Single cell suspension were obtained by grinding liver 
pieces through a 70 μM cell strainer. Nuclei were isolated as described previously (59) and 
sonicated with the UCD-300 Bioruptor (Diagenode), to generate DNA-fragment sizes of 0.2–0.5 kb. 
The following antibodies were used for immunoprecipitations: RXRα (sc-553, Santa Cruz), Pol II 
(sc-9001, Santa Cruz), Pol II-S2P (ab5095, Abcam) and LXR (55). Following RNAse A 
(Fermentas) and proteinase K (Fermentas) treatment, immunoprecipitated DNA was purified using 
the QIAquick PCR purification kit (Qiagen)	 and analyzed by quantitative real-time PCR (primer 
sequences are listed in	 Table S3) and relative occupancies were normalized to input DNA (fold 
difference= 2 –Ct-sample-Ct-input). To control for non-specific binding, a 82 base pair fragment in a gene 
desert in chromosome 6 (ActiveMotif) was used. 
 
RNA sequencing and analysis 
Total RNA was extracted using TRIzol (Life technologies) and cDNA libraries were prepared using 
the Stranded mRNA-Seq Kit (Kapa Biosystems). Briefly, poly-A tailed RNA was purified using 
paramagnetic oligo-dT beads from 200 nanograms of total RNA, with a RNA Integrity Number 
above 7.5 as determined by the Agilent Bioanalyzer. The purified RNA was chemically fragmented 
and cDNA was synthesised using random primers (Kapa Biosystems). Adapter-ligated DNA library 
was amplified with 12 cycles of PCR and library fragment was estimated using the Agilent 
TapeStation 2200.Library concentration was determined using the Qubit DNA HS assay (Life 
Technologies). Libraries were sequenced on an Illumina NextSeq 500, NCS v2.1.2 (Illumina) with 
a 43bp paired end protocol. Basecalling was done using standard Illumina parameters (RTA 
2.4.11). Sequencing and pipeline analysis was performed by UCL Genomics (London, UK). Reads 
were demulitplexed using Illumina’s bcl2fastq v2.17 and aligned using STAR v2.5.0b to the mouse 
GRCm38/mm10 reference sequence. Transcript abundance was estimated using Illumina's 
RnaReadCounter tool and differential expression analysis performed with DESeq2, which uses the 
Benjamin-Hochberg method for multiple testing correction. Pathway enrichment analysis was 
performed with the Gene Set Enrichment Analysis (GSEA) software’s pre-ranked module (60) and 
g:profiler (http://biit.cs.ut.ee/gprofiler/index.cgi). Top regulated genes were confirmed by qPCR on 
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a separate set of liver samples from HFHC-fed mice. Heatmaps were created using raw gene 
count values with the MultiExperiment Viewer (MeV) software (61). Clustered heatmaps were 
created with Heatmapper Expression tool (http://www1.heatmapper.ca/expression/) and Venn 
diagrams using a BGE tool (http://bioinformatics.psb.ugent.be/webtools/Venn/). 
 
Statistical analysis.  
Data is presented as mean ± SEM. Differences were considered significant at p < 0.05 by a two-
tailed Student t-test. For multiple comparisons, significance was assessed by single variance 
ANOVA followed by Student’s T-test. The F-statistic (dfbetween=3, dfwithin=15) and the P value for the 
significant main effect are shown. 
 
Data availability. Gene expression RNAseq data have been deposited at the NCBI Gene 
Expression Omnibus (GEO) accession numbers are GSE9665 (chow) and GSE95359 (HFHC). 
The authors declare that all data supporting the findings of this study are available within the article 
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Figure 1. LXRa-S196A mice develop enhanced steatosis on a high cholesterol diet. (a) 
LXRα-Ser196 phosphorylation analysed by LXRα/β immunoprecipitation of liver homogenates and 
immunoblotting with a phospho-S196-LXRa specific antibody. Global LXRα expression was 
assessed. (b) Hepatic non-esterified fatty acids (NEFAs) and triglycerides (TGs) in mice fed a 
HFHC diet (n=6/group) normalized to liver protein levels. (c) Kleiner’s scores for steatosis (0-3) of 
liver sections (n≥5/group). (d) Representative images of Haematoxylin and Eosin (H&E) stained 
liver sections from mice fed chow or HFHC diet. Scale bar at 50 μM. (e) Distribution of lipid 
droplets by area in H&E-stained liver sections (n=6/group). Area distribution was compared by chi-
square test for trend (p= 0.0003). (f) Hepatic gene expression in mice fed a HFHC diet 
(n=6/group). Normalized data shown relative to WT, set as 1. (g) De novo lipogenesis (DNL) index 
measured as the ratio of 16:0 (Palmitate) and 18:2 n-6 (Linoleic) content in liver (n=6/group). (h) 
Hepatic fatty acid levels (n=6/group). Data are means ± SEM. *p<0.05, **p<0.005 or ***p<0.005 
relative to WT. 
 
Figure 2. LXRα-S196A alleviates diet-induced hepatic inflammation and fibrosis.  
(a) Kleiner’s Scores for lobular inflammation (0-3) from liver sections of mice (n=6/group). (b) 
Representative images of Picrosirius Red stained liver sections (left). Scale bar at 100 μM. 
Quantification of stained areas by Image J (n=6/group) (right). Values are the average of positively-
stained area. (c) Hepatic gene expression (n=6/group). Normalized data shown relative to WT. (d) 
Hepatic gene expression in mice fed chow (n=4/group) or HFHC diet (n=6/group). Normalized data 
shown relative to WT chow group. *p<0.05, **p<0.005, ***p< 0.0005, relative to WT chow. (e) 
Hepatic gene expression (n=6/group). Values shown normalized to cyclophilin and relative to WT. 
Data are means ± SEM. *p<0.05, **p<0.005 relative to WT. 
 
Figure 3. LXR phosphorylation deficient mice show reduced cholesterol levels in response 
to a HFHC diet. (a) Plasma total cholesterol levels in mice fed a chow (n=4/group) or a HFHC diet 
(n≥5/group). (b) Hepatic total cholesterol levels in mice fed a HFHC diet (n=6/group). Values 
shown are normalized to protein levels in tissue homogenates. (c) Hepatic gene expression in fed 
	 29 
a HFHC diet (n=6/group). Normalized data shown relative to WT. (d-e) Hepatic gene expression in 
mice fed chow (n=4) or a HFHC diet (n=6). Normalized data shown relative to WT chow group. 
Significance of comparisons between HFHC WT and S196A genotypes is shown in c). (f) 
Quantification of free oxysterols in plasma of mice fed a HFHC diet (n=6/group). Data are means ± 
SEM. *p<0.05, **p<0.005, ***p<0.0005, ****p<0.00005 relative to WT. ##p<0.005, 4 vs 6 weeks. 
 
Figure 4. Changes in LXRα phosphorylation reprogram hepatic gene expression. (a) 
Principal Component (PC) Analysis plot showing RNAseq samples analysed by diet and genotype. 
(b) Venn diagram of genes regulated by LXRaS196A compared to LXRaWT (p<0.05) in the 
indicated diets. Numbers of upregulated and downregulated genes are depicted in green and red 
respectively. (c) Volcano plot of log2 ratio vs p-value of differentially expressed genes comparing 
S196A and WT livers exposed to a HFHC (n=3/group). Blue line indicates adjusted p-value 
threshold of 0.04 (Wald Test for logistic regression). (d) GSEA analysis showing enriched 
pathways in S196A livers with p<0.5 (100 permutations) derived from HALLMARK gene sets. (e) 
Heatmaps of hepatic RNAseq raw gene counts (n=3/genotype) for fatty acid and triglyceride 
metabolism, (f) Fold-change of hepatic RNAseq gene counts in S196A compared to WT mice fed a 
HFHC diet (n=3/genotype). Heatmaps of hepatic RNAseq gene counts (n=3/genotype) for (g) 
fibrosis and (h) human NAFLD signature genes. Hepatic gene expression by qPCR of top (i) 
upregulated and (j) downregulated genes from the RNAseq analysis on experimentally-
independent WT and S196A livers (n=6/genotype). Normalized data shown relative to WT as mean 
± SEM. *p<0.05, **p<0.005 or ***p<0.005 relative to WT. 
 
Figure 5. LXRα phosphorylation at S196 affects LXR and TBLR1 occupancy. (a-c) LXR, RXR 
and TBLR1 occupancy at Ces1f (a) and Cyp2c69 (b) identified DR4 sequences and Srebp-1c 
LXRE (c) or a region within in a gene desert (Neg S) in livers of mice fed HFHC for 6 weeks 
(n≥3/genotype). Results shown normalized to input and relative to WT. (d) RNA Pol II and pSer2-
Pol II occupancy at Ces1f, Cyp2c69 and Srebp1c TSS in livers of WT and S196A mice fed a 




Figure 6. LXRα phosphorylation at S196 acts as a novel nutritional sensor and alters 
hepatic lipid metabolism. 
Impaired phosphorylation at LXRα-S196 reprograms the hepatic transcriptome in mice in response 
to a HFHC diet, leading to an increase in de novo lipogenesis and higher degree of steatosis, and 
counterintuitively, reduced hepatic inflammation and fibrosis (steatohepatitis). 
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